New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
16:18 EDTACRXAcelRx Chief Commercial Officer David Chung resigns
AcelRx Pharmaceuticals announced that David Chung has resigned as Chief Commercial Officer in order to assume the role of CEO of a medical device company. Richard King, the company's President and CEO, will assume the duties and responsibilities of the Chief Commercial Officer, and will lead the continued build-out of the commercial organization and launch preparation for Zalviso until a suitable replacement is found. The Company has begun a search for Mr. Chung's replacement.
News For ACRX From The Last 14 Days
Check below for free stories on ACRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
07:06 EDTACRXGuggenheim to hold a conference
Subscribe for More Information
August 18, 2014
10:57 EDTACRXOptions with decreasing implied volatility
Subscribe for More Information
August 11, 2014
16:05 EDTACRXAcelRx says disappointed on Zalviso CRL, to meet with FDA in September
"We were disappointed with the receipt of a Complete Response Letter for Zalviso and we look forward to meeting with the FDA to clarify the items included in the CRL and to discuss our planned response," stated Richard King, president and CEO of AcelRx. "We have spoken to the FDA and plan to meet with them by the end of September 2014. We anticipate we can refile the Zalviso NDA before the end of 2014, pending the outcome of the meeting with the FDA. We remain confident in the Zalviso development program and will work closely with the FDA to address the Agency's concerns as outlined in the CRL to ensure that healthcare professionals and patient communities will have access to Zalviso." The company reiterates and issues financial guidance for the year for total operating expenses to be in the range of $48M-$52M. Estimates cash, cash equivalents and investment balances at December 31 of at least $65M.
16:03 EDTACRXAcelRx reports Q2 EPS (30c), consensus (26c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use